Q-omics provides the consensus-scored GSTM1 profile across patient tissues and cancer cell-line models. GSTM1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, GSTM1 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, GSTM1 RNA expression shows 5,149 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, UCEC, and TGCT as cancer lineages where GSTM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSTM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSTM1 survival associations across molecular data types. GSTM1 RNA expression shows survival associations in the most cancer types (20), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSTM1 RNA expression–survival associations across cancer types. High GSTM1 expression shows unfavorable associations in COAD, BLCA and KIRP, but favorable associations in KIRC, ACC and OV. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for GSTM1 RNA expression.
This table summarizes GSTM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2, while mass-spec protein shows differences in 2. The strongest signals are observed in UCEC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GSTM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSTM1 shows lower tumor expression in UCEC and PRAD. The UCEC box plot shows higher GSTM1 RNA expression in normal versus tumor tissue (log2 FC = −1.449, t-test p = .029).
This table shows molecular features associated with GSTM1 in patient tissues and cancer cell lines. In patient samples, GSTM1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GSTM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
